Alpha 2.0
Login Register
» Authors » Akalushi Muthukumarana

Akalushi Muthukumarana

Explore the profile of Akalushi Muthukumarana including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 75
Followers 0
Related Specialties
General Medicine
Pharmacology
Science
Top 10 Co-Authors
Ryan M Fryer
Roger M Dinallo
Louise K Modis
Paul C Harrison
Kyle E Harrington
Glenn A Reinhart
Rong Rhonda Chen
Daniel Kuzmich
Christian Harcken
Khing Jow Ng
Published In
J Pharmacol Exp Ther
PLoS One
Front Pharmacol
J Cardiovasc Pharmacol
Affiliations
Soon will be listed here.
Recent Articles
1.
Physical Properties and Effect in a Battery of Safety Pharmacology Models for Three Structurally Distinct Enteric Polymers Employed as Spray-Dried Dispersion Carriers
Fryer R, Patel M, Zhang X, Baum-Kroker K, Muthukumarana A, Linehan B, et al.
Front Pharmacol . 2016 Oct; 7:368. PMID: 27790142
Establishing a wide therapeutic index (TI) for pre-clinical safety is important during lead optimization (LO) in research, prior to clinical development, although is often limited by a molecules physiochemical characteristics....
2.
CCR1 plays a critical role in modulating pain through hematopoietic and non-hematopoietic cells
Lewis N, Muthukumarana A, Fogal S, Corradini L, Stefanopoulos D, Adusumalli P, et al.
PLoS One . 2014 Aug; 9(8):e105883. PMID: 25170619
Inflammation is associated with immune cells infiltrating into the inflammatory site and pain. CC chemokine receptor 1 (CCR1) mediates trafficking of leukocytes to sites of inflammation. However, the contribution of...
3.
G protein-coupled bile acid receptor 1 stimulation mediates arterial vasodilation through a K(Ca)1.1 (BK(Ca))-dependent mechanism
Fryer R, Ng K, Nodop Mazurek S, Patnaude L, Skow D, Muthukumarana A, et al.
J Pharmacol Exp Ther . 2014 Jan; 348(3):421-31. PMID: 24399854
Bile acids (BAs) and BA receptors, including G protein-coupled bile acid receptor 1 (GPBAR1), represent novel targets for the treatment of metabolic and inflammatory disorders. However, BAs elicit myriad effects...
4.
The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P₁) and hypertension (S1P₃) in rat
Fryer R, Muthukumarana A, Harrison P, Mazurek S, Chen R, Harrington K, et al.
PLoS One . 2013 Jan; 7(12):e52985. PMID: 23285242
Sphingosine-1-phospate (S1P) and S1P receptor agonists elicit mechanism-based effects on cardiovascular function in vivo. Indeed, FTY720 (non-selective S1P(X) receptor agonist) produces modest hypertension in patients (2-3 mmHg in 1-yr trial)...
5.
Strategic integration of in vivo cardiovascular models during lead optimization: predictive value of 4 models independent of species, route of administration, and influence of anesthesia
Fryer R, Harrison P, Muthukumarana A, Nodop Mazurek S, Ng K, Chen R, et al.
J Cardiovasc Pharmacol . 2011 Dec; 59(4):369-76. PMID: 22179024
The strategic integration of in vivo cardiovascular models is important during lead optimization to enable a wide therapeutic index for cardiovascular safety. However, under what conditions (eg, species, route of...
6.
Mitigation of off-target adrenergic binding and effects on cardiovascular function in the discovery of novel ribosomal S6 kinase 2 inhibitors
Fryer R, Muthukumarana A, Chen R, Smith J, Mazurek S, Harrington K, et al.
J Pharmacol Exp Ther . 2011 Dec; 340(3):492-500. PMID: 22128344
We previously reported the discovery of a novel ribosomal S6 kinase 2 (RSK2) inhibitor, (R)-5-Methyl-1-oxo-2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,2-a] indole-8-carboxylic acid [1-(3-dimethylamino-propyl)-1H-benzoimidazol-2-yl]-amide (BIX 02565), with high potency (IC(50) = 1.1 nM) targeted for the...